Vidcast:  https://youtu.be/YiQl5cMZ-Bk   Patients receiving immunotherapy or genetic-targeted therapy recover just fine from CoVid infections.  A Spanish study of 50 CoVid patients with advanced melanoma was just uploaded to the pre-print server medrixiv.org.   In this small non-randomized study, the group of 22 melanoma patients on checkpoint immunotherapy had a 44% better survival rate than those on no therapy.  The 16 patients on targeted BRAF/MEK inhibitor therapy had a 41% better survival rate.   If you have a serious medical problem like advanced melanoma, work closely with your doctors to plan ongoing therapy.  Additional studies like this one will help decision making.  Don’t run scared of CoVid and compromise treatment of more serious problems.   https://www.medrxiv.org/content/10.1101/2020.05.19.20106971v1   #covid #pandemic #cancer #immunotherapy #melanoma